Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis

BACKGROUND: The interleukin-23p19-subunit inhibitor guselkumab effectively treats signs and symptoms of psoriatic arthritis (PsA). We evaluated the effect of guselkumab on fatigue. METHODS: Across two phase 3 trials of guselkumab (DISCOVER-1, DISCOVER-2), patients with active PsA despite standard th...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahman, Proton, Mease, Philip J., Helliwell, Philip S., Deodhar, Atul, Gossec, Laure, Kavanaugh, Arthur, Kollmeier, Alexa P., Hsia, Elizabeth C., Zhou, Bei, Lin, Xiwu, Shawi, May, Karyekar, Chetan S., Han, Chenglong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278683/
https://www.ncbi.nlm.nih.gov/pubmed/34261541
http://dx.doi.org/10.1186/s13075-021-02554-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278683/
https://www.ncbi.nlm.nih.gov/pubmed/34261541
http://dx.doi.org/10.1186/s13075-021-02554-3

Ejemplares similares